December 31, 2020
August 18, 2020
The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has resulted in a highly segmented space dominated by…
The high number of premium-priced non-small-cell lung cancer (NSCLC) therapies and the large number of NSCLC patients have resulted in a significant financial burden for payers. Costs are set to…
December 11, 2019
November 19, 2019
November 6, 2019
MARKET OUTLOOKNon-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, which results in a significant financial burden on payers. Costs are set to…
December 24, 2018
December 12, 2018